More Rules, Still Exceptions: Understanding Immunomodulatory Antibody Activity In Vivo
- PMID: 29634942
- DOI: 10.1016/j.ccell.2018.03.016
More Rules, Still Exceptions: Understanding Immunomodulatory Antibody Activity In Vivo
Abstract
Understanding how agonistic and checkpoint control antibodies mediate their activity in vivo is essential for further development of these promising anti-cancer therapies. In this issue of Cancer Cell, studies by Vargas et al. and Yu et al. provide insights into the mode of action of CTLA-4- and CD40-specific antibodies.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22. Cancer Cell. 2018. PMID: 29576375 Free PMC article.
-
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22. Cancer Cell. 2018. PMID: 29576376 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
